Table 3.
Overview of the results of the in vitro antitumor screening for compounds 12a–c and 17t,u.a
| Comp | no. Studiede | pGI50b |
pTGIc |
pLC50d |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| no. giving positive resultse | range | MG_MIDf | no. giving positive resultse | range | MG_MIDf | no. giving positive resultse | range | MG_MIDf | ||
| 12a | 58 | 58 | 6.18–4.59 | 5.36 | 30 | 5.53–4.00 | 4.31 | 2 | 4.44–4.00 | 4.01 |
| 12b | 58 | 58 | 6.58–4.82 | 5.65 | 29 | 6.06–4.00 | 4.53 | 7 | 5.19–4.00 | 4.06 |
| 12c | 52 | 52 | 6.64–5.47 | 5.99 | 23 | 6.18–4.00 | 4.58 | 10 | 5.02–4.00 | 4.07 |
| 17t | 59 | 59 | 7.27–4.67 | 6.05 | 44 | 6.41–4.00 | 4.71 | 17 | 4.94–4.00 | 4.10 |
| 17u | 57 | 57 | 6.78–4.41 | 5.97 | 32 | 6.17–4.00 | 4.62 | 8 | 4.90–4.00 | 4.05 |
a
Data obtained from the NCI’s in vitro disease-oriented human tumor cells screen.
b
pGI50 is the –log of the molar concentration that inhibits 50% net cell growth.
c
pTGI is the –Log of the molar concentration giving total growth inhibition.
d
pLC50 is the –Log of the molar concentration leading to 50% net cell death.
e
Refers to the number of cell lines.
f
MG_MID = mean graph midpoint = arithmetical mean value for all tested cancer cell lines. If the indicated effect was not attainable within the used concentration interval, the highest tested concentration was used for the calculation.